FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Federal Judge Blocks Trump Administration’s Pause on New Wind-Energy Permits 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
International Outcry Grows Over Re-Arrest of Nobel Laureate Narges Mohammadi in Iran 
U.S. Dollar Slides for Third Straight Week as Rate Cut Expectations Boost Euro and Pound 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
China’s Small Bank Consolidation Struggles as Profits Fall and Risks Persist 
Oil Prices Rebound in Asia as Venezuela Sanctions Risks Offset Ukraine Peace Hopes 
Johnson & Johnson offered $8.9 billion to settle years-old lawsuits claiming that its talcum powder products caused cancer.
The New Jersey-based pharmaceutical giant described their proposal, which still needs a bankruptcy court’s approval, as an equitable and efficient resolution to all claims arising from cosmetic talc litigation.
If approved by the bankruptcy court and a majority of the claimants, the $8.9 billion deal would rank alongside those reached by cigarette corporations and opioid producers as one of the largest product liability settlements ever in the US
Thousands of claims have been filed against J&J because of talcum powder that may have contained traces of asbestos and was linked to ovarian cancer.
The company has never acknowledged wrongdoing, but as of May 2020, it no longer sells its talc-based baby powder in the US and Canada.
The $8.9 billion would be paid to the tens of thousands of claimants over 25 years through a J&J subsidiary, LTL Management LLC, which was set up to address the claims and has filed for bankruptcy protection.
A previous settlement involving LTL was rejected by an appellate court.
